Often the cause of gut symptoms remains unidentified. Feanalytic develops a new quick and non-invasive diagnostic assay to detect and monitor Inflammatory bowel disease (IBD) and its subtypes. The new diagnostic tool will improve IBD diagnosis and personal treatment.

Our method is based on detection of keratin biomarkers from stool samples. The patented method enables patient-friendly diagnosis of IBD disease and its specific subtypes. Improved noninvasive IBD diagnostics will benefit both patients and healthcare providers.